Cancer mucosa antigens as a novel immunotherapeutic class of tumor-associated antigen.
Colorectal cancer is a leading cause of cancer-related mortality worldwide. Surgery and chemoradiation exhibit incomplete efficacy and, ultimately, 50% of patients die of metastatic disease. In the context of that unmet clinical need, immunotherapeutic approaches have enjoyed limited success, partly because of a paucity of suitable antigen targets. However, exploitation of immune compartmentalization, employing antigens with expression restricted to normal intestinal mucosa and derivative colorectal tumors--cancer mucosa antigens (CMAs)--may represent a previously unrecognized class of immune targets supporting efficacious antitumor immunotherapy. Guanylyl cyclase C (GCC) is an intestine/colorectal cancer-restricted protein ideally suited as the first CMA for clinical evaluation.
Snook
A E
AE
Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Eisenlohr
L C
LC
Rothstein
J L
JL
Waldman
S A
SA
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000276:immunology / Q000494:pharmacology*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000276:immunology; D006162:Guanylate Cyclase / Q000276:immunology* / Q000494:pharmacology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007413:Intestinal Mucosa / Q000276:immunology*; D009369:Neoplasms / Q000188:drug therapy; D000074261:Receptors, Enterotoxin; D050705:Receptors, Guanylate Cyclase-Coupled; D018000:Receptors, Peptide / Q000276:immunology*
D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D018000:Receptors, Peptide; D006162:Guanylate Cyclase; D000074261:Receptors, Enterotoxin; D050705:Receptors, Guanylate Cyclase-Coupled